Previous 10 | Next 10 |
I had an hour phone conversation with Scynexis ( SCYX ) CEO Marco Taglietti last week. Key takeaways are summarized below. Data so far shows that Scynexis clearly has a novel antifungal asset, which can be used in both outpatient and hospitalized patient settings. The oral form of Ibrexafung...
Shares of SCYNEXIS ( SCYX ) have risen by 25% since my January update piece highlighted encouraging data from the FURI study and reiterated my expectations of near-term upside. The stock offered a nice run-up opportunity, with shares rising as high as 75% before pulling back over the past fe...
WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new additi...
WASHINGTON , July 1, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG) announced today the addition of X-Biotix Therapeutics, Inc. (X-Biotix) to its coalition of companies with the mission to combat drug resistant infections and spur life-saving innovations. This new additi...
JERSEY CITY, N.J. , June 25, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the availability of nine presentations (here) from the America...
WASHINGTON , June 20, 2019 /PRNewswire/ -- The Antimicrobials Working Group (AWG), a coalition of companies with the mission to combat drug-resistant infections and spur life-saving innovations, today announced that eleven of its member companies will present data from their clinical...
Recently in the journal Nature , an article was published characterizing the oldest known example of a fungus. The organism, termed an Ourasphaira, was approximately one billion years old and was found in what was believed to be an ancient river bed in Canada. For comparison sake, the oldes...
JERSEY CITY, N.J. , June 14, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced the appointment of Nkechi Azie , MD, MBA, FIDSA, as Vice President of Cli...
The DISARM Act of 2019 provides the framework needed to stabilize the antimicrobial ecosystem, spur development of new infection-fighting drugs, and preserve the effectiveness of existing medicines for drug-resistant infections WASHINGTON , June 7, 2019 /PRNewswire/ -- The Antimi...
JERSEY CITY, N.J. , June 5, 2019 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that a total of nine presentations revealing data which further d...
News, Short Squeeze, Breakout and More Instantly...
JERSEY CITY, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that it will receive a $10 million development milestone payment un...